These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 7419900)

  • 1. Estrogen receptor cytochemistry by fluorescent estrogen.
    Nenci I; Dandliker WB; Meyers CY; Marchetti E; Marzola A; Fabris G
    J Histochem Cytochem; 1980 Oct; 28(10):1081-8. PubMed ID: 7419900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flow cytometric determination of estrogen receptors in intact cells.
    Oxenhandler RW; McCune R; Subtelney A; Truelove C; Tyrer HW
    Cancer Res; 1984 Jun; 44(6):2516-23. PubMed ID: 6722791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estradiol membrane binding sites on human breast cancer cell lines. Use of a fluorescent estradiol conjugate to demonstrate plasma membrane binding systems.
    Berthois Y; Pourreau-Schneider N; Gandilhon P; Mittre H; Tubiana N; Martin PM
    J Steroid Biochem; 1986 Dec; 25(6):963-72. PubMed ID: 3025520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluoresceinated estrone binding by human and mouse breast cancer cells.
    Fisher B; Gunduz N; Zheng S; Saffer EA
    Cancer Res; 1982 Feb; 42(2):540-9. PubMed ID: 7055802
    [No Abstract]   [Full Text] [Related]  

  • 5. Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status.
    Lønning PE; Helle H; Duong NK; Ekse D; Aas T; Geisler J
    J Steroid Biochem Mol Biol; 2009 Oct; 117(1-3):31-41. PubMed ID: 19591931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrone receptor formation during the processing of estradiol-receptor complex in MCF-7 cells.
    Hansen ER; Brooks SC
    Cancer Res; 1982 May; 42(5):1967-74. PubMed ID: 7066908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Affinity cytochemistry visualizes specific estrogen binding sites on the plasma membrane of breast cancer cells.
    Nenci I; Marchetti E; Marzola A; Fabris G
    J Steroid Biochem; 1981 Nov; 14(11):1139-46. PubMed ID: 7311527
    [No Abstract]   [Full Text] [Related]  

  • 8. Fluorescent ligands, used in histocytochemistry, do not discriminate between estrogen receptor-positive and receptor-negative human tumor cell lines.
    Berns EM; Mulder E; Rommerts FF; Blankenstein RA; de Graaf E; van der Molen HJ
    Breast Cancer Res Treat; 1984; 4(3):195-204. PubMed ID: 6487821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of high-performance liquid chromatography in the evaluation of the synthesis and binding of fluorescein linked steroids to estrogen receptors.
    Lonsdorfer M; Clements NC; Wittliff JL
    J Chromatogr; 1983 Aug; 266():129-39. PubMed ID: 6630343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytofluorometric analysis for estrogen receptors using fluorescent estrogen probes.
    Kute TE; Linville C; Barrows G
    Cytometry; 1983 Sep; 4(2):132-40. PubMed ID: 6685018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen receptors in human breast cancer. I. Specificity of the histochemical localization of estrogen receptors using an estrogen-albumin FITC complex.
    van Marle J; Lindeman J; Ariens AT; Labruyère W; van Weeren-Kramer J
    Virchows Arch B Cell Pathol Incl Mol Pathol; 1982; 40(1):17-25. PubMed ID: 6126951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of plasma estrogen sulfates in mammary cancer cells.
    Vignon F; Terqui M; Westley B; Derocq D; Rochefort H
    Endocrinology; 1980 Apr; 106(4):1079-86. PubMed ID: 6244140
    [No Abstract]   [Full Text] [Related]  

  • 13. Flow cytometric analysis of fluorescein-conjugated estradiol (E-BSA-FITC) binding in breast cancer suspensions.
    Benz C; Wiznitzer I; Lee SH
    Cytometry; 1985 May; 6(3):260-7. PubMed ID: 3996141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The biodistribution of Br-77-labeled estrone: visualization of tissues containing increased estrogen receptors.
    Spicer JA; Preston DF; Baranczuk RJ; Harvey E; Guffey MM; Bradshaw DL; Robinson RG
    J Nucl Med; 1979 Jul; 20(7):761-5. PubMed ID: 541714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of hormone-receptor interactions by means of fluorescence labeling.
    Dandliker WB; Brawn RJ; Hsu ML; Brawn PN; Levin J; Meyers CY; Kolb VM
    Cancer Res; 1978 Nov; 38(11 Pt 2):4212-24. PubMed ID: 212190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential antineoplastics. 4th communication: N-mustard derivatives of estrone).
    Hamacher H
    Arzneimittelforschung; 1979; 29(3):463-6. PubMed ID: 582728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oestrogen receptors in human breast cancer: review of histopathological correlations and critique of histochemical methods.
    Underwood JC
    Diagn Histopathol; 1983; 6(1):1-22. PubMed ID: 6307615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, estrogen receptor binding affinity and biological evaluation of some 2-substituted estrone derivatives.
    Omar AM; AboulWafa OM; Labouta IM; el-Tombary AA; el-Mallah AI
    Farmaco; 1997 Apr; 52(4):219-25. PubMed ID: 9241826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluoresceinated estrone binding by cells from human breast cancers obtained by needle aspiration.
    Gunduz N; Zheng S; Fisher B
    Cancer; 1983 Oct; 52(7):1251-6. PubMed ID: 6883288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical response to hormone therapy correlated with estrogen receptor analyses. Biochemical v histochemical methods.
    McCarty KS; Hiatt KB; Budwit DA; Cox EB; Leight G; Reintgen D; Georgiade G; McCarty KS; Siegler HF
    Arch Pathol Lab Med; 1984 Jan; 108(1):24-6. PubMed ID: 6546332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.